Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis

CONCLUSIONSThe results of this retrospective study suggest a possible survival benefit for the use of octreotide LAR in elderly patients with distant‐stage NET with carcinoid syndrome. The results of the current study also suggest that octreotide LAR is underused in this population despite recommended guidelines. Cancer 2014. © 2014 American Cancer Society.

Source: Cancer - March 26, 2014 Category: Cancer & Oncology Authors: Chan Shen, Ya‐Chen Tina Shih, Ying Xu, James C. Yao Tags: Original Article Source Type: research